Status:

ACTIVE_NOT_RECRUITING

Efficacy and Safety of Tirofiban for Patients With BAD (BRANT)

Lead Sponsor:

Peking Union Medical College Hospital

Collaborating Sponsors:

Pharmaron (Chengdu) Clinical Services Co., Ltd.

Conditions:

Branch Atheromatous Disease

Eligibility:

All Genders

18-75 years

Phase:

PHASE3

Brief Summary

Branch atheromatous disease (BAD)-related stroke, characterized by subcortical single infarcts without severe stenosis of the large artery, but with a clear atherosclerotic mechanism, is now regarded ...

Detailed Description

BRANT study is a multicenter, randomized, open label, blinded endpoint, Parallel controlled trial with the primary null hypothesis that, in patients with acute BAD-related stroke, there is no differen...

Eligibility Criteria

Inclusion

  • Age: 18-75 years old
  • Acute ischemic stroke
  • Time from onset to randomization ≤48h; if onset time is unknown, time from last known well to randomization ≤48h
  • Meet the following BAD Diagnostic Imaging Criteria
  • 1. DWI infarcts: single (isolated) deep (subcortical) infarcts;
  • 2. The culprit arteries are either Lenticulostriate artery (LSA) or Paramedian pontine artery (PPA), and the infarct lesion on DWI conforms to one of the following characteristics (A/B): A. LSA: 1) "Comma-like" infarct lesions with "Fan-shaped" extension from bottom to top in the coronary position; or 2) ≥ 3 layers (layer thickness 5-7 mm) on axial DWI brain images; B. PPA: The infarct lesion extends from the deep pons to the ventral pons on the axial DWI brain images;
  • 3. No more than 50% stenosis on the parent artery of the criminal artery (i.e. corresponding basilar or middle cerebral artery) (Confirmed by magnetic resonance angiography \[MRA\] or computed tomography angiography \[CTA\] or digital substraction angiography \[DSA\]).
  • Singed informed consent by the patient or legally authorized representatives.

Exclusion

  • Transient ischemic attack (TIA)
  • Intracranial hemorrhagic diseases, vascular malformations, aneurysms, brain abscesses, malignant space-occupying lesions, or other non-ischemic intracranial lesions detected by baseline CT/MRI, or MRA/CTA/DSA;
  • Presence of ≥50% stenosis in extracranial artery in tandem relationship ipsilateral to the lesion;
  • Cardiogenic embolism: atrial fibrillation, myocardial infarction, heart valve disease, dilated cardiomyopathy, infective endocarditis, atrioventricular block disease, heart rate less than 50 beats per minute
  • Have received or plan to receive endovascular therapy or thrombolysis after onset;
  • Stroke of other clear causes, e.g., moyamoya disease, arterial entrapment, vasculitis, etc.
  • modified Rankin Scale ≥2 before onset
  • Use of tirofiban within 1 week before or after onset
  • Low platelets (\<100×10\^9 /L), or Prothrombin time \>1.3 times of the upper normal limit, or INR \>1.5, or other systemic hemorrhagic tendencies such as hematologic disorders
  • Elevation of ALT or AST more than 1.5 times the upper normal limit;
  • Glomerular filtration rate \<60 ml/min/1.73m\^2
  • Known malignant tumors
  • History of trauma or major surgical intervention within 6 weeks prior to onset
  • History of intracranial hemorrhage
  • Active or recent history(within 30 days prior to onset) of clinical bleeding (e.g., gastrointestinal bleeding)
  • Malignant hypertension (systolic blood pressure \>200 mmHg, or diastolic blood pressure \>120 mmHg)
  • Life expectancy ≤ 6 months
  • Contraindications of 3 T MRI examination
  • Pregnant or lactating women
  • Have participated in another clinical trial within 3 months prior to the date of informed consent, or are participating in another clinical trial.

Key Trial Info

Start Date :

November 9 2023

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 20 2026

Estimated Enrollment :

516 Patients enrolled

Trial Details

Trial ID

NCT06037889

Start Date

November 9 2023

End Date

March 20 2026

Last Update

January 7 2026

Active Locations (25)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 7 (25 locations)

1

Peking Union Medical College Hospital

Beijing, Beijing Municipality, China, 100730

2

Beijing Shunyi Hospital

Beijing, Beijing Municipality, China, 101300

3

Beijing Shijitan Hospital, Capital Medical University

Beijing, Beijing Municipality, China

4

The First Hospital of Tsinghua University

Beijing, Beijing Municipality, China

Efficacy and Safety of Tirofiban for Patients With BAD (BRANT) | DecenTrialz